Enzyme engineering: An innovative way to manage the economics of biosimilars- Polyclone case study
Biocatalytic processes are used to synthesize antibiotics and chiral intermediates for pharmaceuticals
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Biocatalytic processes are used to synthesize antibiotics and chiral intermediates for pharmaceuticals
The purpose of stability testing is to provide evidence on how the
Biosimilars are biological products manufactured after expiry of the patent of innovator
Although the breakthroughs in biologicals have been groundbreaking, the future of health
Over the last 2-3 decades biologics have changed the way many
Biopharmaceuticals are a cornerstone of therapy for a wide spectrum of disorders
Tangential flow filtration (TFF) using ultrafiltration membranes are commonly used for the
assays are one of the most popular and routinely used analytical techniques for the bioanalysis of biosimilars. For dependable results, drug specific ligand binding assay development and fit for purpose
Manufacturers of biologicals are required to demonstrate that their downstream processes are
Osteomyelitis especially chronic osteomyelitis is a severe and challenging setback in bone
High-pH anion exchange chromatography method coupled with pulsed amperometric detection (HPAEC
Monoclonal antibodies are gaining prominence as therapeutic agents to treat a wide
Legislation enacted in 2010 as part of the Affordable Care Act established
Unlike small molecules, biological medicinal products are complex in nature. Despite the
Intellectual property particularly patents are considered to be road blocks in the
The presentations address the procedural and patentability aspects of the grant and
Intellectual property law enables and gives proper direction along with the rules
Various blockbuster Biologics go off patent by 2020 creating a huge opportunity
The new decade has foreseen significant changes reinvigorating the market for biosimilars
Patenting is translating of intangible assets to tangible and is considered to
With clarity concerning the Biologics Price Competition & Innovation Act (BPCIA) of 2010
Biologic medicines, though expensive, are in growing demand as they target variety
This presentation will cover approaches needed for successful characterization of impurities and
This session will focus on safety-related aspects of biosimilars development; noting
Biosimilars/Biologics are given various names in different countries: Biosimilars in the
For authors and organisers
Find the right journal for your paper and submit your manuscript.